Oncology

Immatics is prioritizing its TCR-T and TCER cell therapy programs and leaving behind its first-generation programs.

Study authors Matthew Charman, PhD, and Matthew D. Weitzman, PhD, elaborated on the findings and implications of their research.

Although the TCB-202-001 trial ended prematurely due to the COVID-19 pandemic, promising results warrant a phase 2 trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Precigen’s investigational UltraCAR-T therapy is being assessed in a dose-escalation and -expansion study that will include patients with solid tumors, chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and diffuse large B-cell lymphoma.

Review top news and interview highlights from the week ending March 31, 2023.

CB-011 and CB-010 are being evaluated for the treatment of r/r multiple myeloma and r/r B-cell non-Hodgkin lymphoma, respectively.

The Study Safety Committee has recommended that the trial proceed to enroll patients in the highest-dose cohort.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA will determine the acceptability of the BLA within the next 60 days.

The patient was treated at the new fifth dose level and had concomitant metapneumovirus infection.

Investigators plan to present full results from the OS analysis of the phase 3 ZUMA-7 trial at an upcoming medical meeting.

The barrier is an essential part of keeping the brain safe, but it also prevents the immune system from eliminating brain cancer tumors.

Patients in the UK with r/r multiple myeloma may still be able to access the CAR-T through ongoing clinical trials, which are not impacted by the decision.

Review top news and interview highlights from the week ending March 17, 2023.

Nirav N. Shah, MD, associate professor at the Medical College of Wisconsin in Milwaukee, discussed the evaluation of LV20.19 CAR in MCL, as well as key efficacy and safety data on the therapy to date.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The announcement comes in light of serious adverse events reported in the phase 1/2 clinical trials for BPX-601.

The investigator-initiated, single-arm, open-label trial will follow 20 patients with high-risk LBCL for 2 years, with a primary outcome measure of complete response rate per Lugano classification.

Alison Betof Warner, MD, PhD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discussed the solid tumor session she chaired at the 2023 Tandem Meetings.

Review top news and interview highlights from the week ending March 10, 2023.

The planned clinical trial of EB103 has received clearance to include patients with HIV-associated lymphoma and primary and secondary central nervous system lymphoma.

Mesoblast’s allogeneic off-the-shelf therapy showed long-term benefit in supporting data among children with steroid-refractory acute graft versus host disease. The FDA has set a PDUFA action date of August 2, 2023, for its review.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

As investigational cell therapies influx the clinical trial landscape, especially for oncologic indications, some companies are ceding the race to their competitors.

The company is back to the drawing board after discontinuing its last clinical-stage program at the end of 2022.

SNK01 is primarily being assessed in combination and as a monotherapy for treating solid tumors.

Review top news and interview highlights from the week ending March 3, 2023.

The associate professor of medicine at Sylvester Comprehensive Cancer Center discussed updated data from the phase 3 ALLELE study.

The vice chair for cellular therapies at Roswell Park Comprehensive Cancer Center discussed new research from the center presented at the 2023 Tandem Meetings.